Author Archives: BPI Staff

Cytovia driving CAR NK manufacturing to Puerto Rico

Cytovia Therapeutics will set up a facility in Aguadilla, Puerto Rico to support production of its off-the-shelf iPSC-derived CAR NK therapeutics. Cell therapy developer Cytovia has signed a long-term joint collaboration manufacturing and operations agreement with BioSciencesCorp to integrate Cytovia’s manufacturing processes within an existing 95,000 square-foot facility. The plant, which will include more than 40,000 square feet of cleanroom and biomanufacturing space, will be located in Aguadilla, Puerto Rico, and the firm says it will recruit manufacturing personnel beginning…

Process intensification and PAT essential for achieving real-time release

Development of complex methods enabling real-time release of therapeutics requires creativity and collaboration, say experts from NIIMBL and SCIEX. Interest in real-time release (RTR) is driving the industry to think about process intensification in a coordinated manner. Process intensification offers the potential for increased efficiencies and thereby reduced cost and time for drug production. Workflows, capital and operating expenses, product quality, and waste production can all be positively impacted. There is consequently a push in the industry to develop and…

Filling in its drug product offering: Cytiva buys Vanrx Pharmasystems

Cytiva’s first acquisition since being acquired by Danaher sees it add robotic aseptic filling machines to its bioprocess offering. Vanrx Pharmasystems, and all 120 staff, will be incorporated into Cytiva, after the bioprocess vendor acquired the Canadian company for an undisclosed fee. Vanrx makes standardized aseptic filling technologies for filling vials, syringes, and cartridges, including its SA25 range of aseptic and lyophilized technologies, and the Microcell Vial Filler – a closed robotic isolator for pharmaceutical vial filling. “For now, this…

Astrea licenses Avacta’s Affimer reagent technology

Gamma Biosciences’ bioseparation business Astrea will use the Affimer technology to expand its range of ligand discovery and development capabilities. Avacta Group’s Affimer reagents are small proteins that have a binding surface that can be tailored to capture a target molecule of interest out of complex mixtures encountered in biomanufacturing. “The Affimer reagent technology was originally developed at the MRC Cancer Unit in Cambridge UK for proteomics applications and was acquired by Avacta in 2012,” Alastair Smith, CEO of Avacta…

Sanofi shells out $1.1bn for immunology MAb maker Kymab

Sanofi will gain global rights to KY1005 and a monoclonal antibody discovery and development platform through the addition of Kymab. French pharma giant Sanofi is paying $1.1 billion upfront for Cambridge, UK-based biotech Kymab with a further $350 million depending on potential milestones. The deal brings the fully humanized monoclonal antibody KY1005 to Sanofi’s pipeline, along with four other early clinical and preclinical candidates. According to the firm, the candidate targets immune system regulator OX40-Ligand, “blocking inappropriate activation and proliferation…

The next frontier of CAR-T cell therapies: Allogeneic workflows

The development of CAR-T cell therapies provides treatment options for some of the most vulnerable cancer patients, giving them a fighting chance to battle their diagnoses if they’re eligible. Researchers and organizations continue to work diligently to optimize the manufacturing process to develop safe and effective CAR-T cell therapies as efficiently as possible, with the hope that one day they can be manufactured at a lower cost and made available to any patient who could benefit from them. Personalized therapies…

Natural killer deal: Sanofi buying Kiadis for $358m

Once the deal goes through, the French pharma giant will add an allogeneic natural killer (NK) cell therapy platform to its immune-oncology capabilities. In cell therapy development, industry has seen some success with T-cells, most notably in the approvals of the chimeric antigen receptor T-cell therapies Kymriah and Yescarta. T cells work by spurring patients’ adaptive immune system, which learns to remember threats and eliminates them when they return. However, NK cells, which are part of our innate immune system,…

Podcast: The impact of COVID-19 on the pharma and bio supply chain

Bioprocess Insider editor Dan Stanton joins an industry panel to discuss supply chain concerns stemming from the ongoing coronavirus crisis. Listen to the podcast now. Brought to you by international pharmaceutical content, digital and design agency ramarketing, the Molecule to Market podcast takes a listen to the contract outsourcing space with industry insights direct from the brains of the people that make the headlines. In this special episode, one of the headline writers – Bioprocess Insider founder and editor Dan…

CellGenix: Serum-free medium offers faster T-cell therapy manufacturing

Freiburg, Germany-based CellGenix says its T-cell medium – CellGenix TCM – offers a serum-free and xeno-free alternative for rapid expansion of functional human T-cells. Due to stable glutamine in the formulation, the medium is ready-to-use for T-cell cultures without the need for supplementation with human serum or glutamine. Many current T-cell therapy protocols rely on the addition of human serum. Eliminating the use of human serum will reduce the failure rate in your manufacturing process due to the high lot-to-lot…